UroGen Pharma (URGN) risk factors

89 risks, 7 new, 6 dropped, 29 reworded since the prior year. Cash balances dropped from $241.7M to $120.5M while commercializing Jelmyto and Zusduri. New debt covenants restrict asset sales, dividends, and borrowing. Israeli operations face severe disruption risks from military reserve call-ups.

88 risks. UroGen is a biotechnology company heavily reliant on the commercial success of its sole approved product, Jelmyto, and its lead candidate, UGN-102. The company has a history of significant net losses, including $126.9 million in 2024, and depends on external financing and debt agreements. Operations are subject to extensive regulatory oversight, complex manufacturing requirements, and intense industry competition.